Molecular basis, potential biomarkers, and future prospects of OSCC and PD-1/PD-L1 related immunotherapy methods

Area of Science:

• Oncology
• Immunotherapy
• Cancer Biology

Background:

• Oral squamous cell carcinoma (OSCC) remains a significant global health challenge with limited treatment success.
• Conventional therapies like surgery, radiation, and chemotherapy offer suboptimal outcomes for many OSCC patients.
• Recent advancements in cancer treatment include immunotherapies targeting the programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) pathway.

Purpose of the Study:

• To systematically review the effectiveness of PD-1/PD-L1 pathway inhibitors in oral squamous cell carcinoma (OSCC).
• To explore the potential of combination therapies involving the PD-1/PD-L1 pathway in OSCC treatment.
• To investigate the role of exosomes and protein-protein interactions within the PD-1/PD-L1 pathway in OSCC.

Main Methods:

• Literature review of recent research on PD-1/PD-L1 pathway in OSCC.
• Analysis of existing studies on immunotherapy effectiveness for OSCC.
• Exploration of mechanistic insights into exosome and protein interactions related to PD-1/PD-L1 signaling.

Main Results:

• The PD-1/PD-L1 pathway shows promise as a therapeutic target in OSCC.
• Combination therapies leveraging PD-1/PD-L1 inhibition may enhance treatment efficacy.
• Exosomes and protein-protein interactions are critical components of PD-1/PD-L1 pathway modulation in OSCC.

Conclusions:

• The PD-1/PD-L1 pathway represents a promising avenue for novel OSCC treatments.
• Further research into combination therapies and mechanistic interactions is crucial for advancing OSCC care.
• Future therapeutic strategies may involve targeting exosomes and protein interactions to optimize PD-1/PD-L1 blockade in OSCC.